AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with this FTSE 100 ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

AstraZeneca said it plans to pump $2 billion in new investment ... parts of which are aimed at lowering drug prices. The ...

Berenberg Bank reissued a “buy” rating and set a £150 ($195.26) price objective on shares of AstraZeneca in a research report ...